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Abstract
Background: Although the interactions between lithium treatment and thyroid function have long been recognised, their
clinical relevance is still controversial. This paper sets out a review of the literature to date, considering that lithium still
represents the gold standard among prophylactic treatments of manic-depression several decades after its introduction.
Method: PubMed database was used to search for English-language articles relating to lithium treatment and thyroid function.
As the amount of relevant papers totalled several hundreds, this review refers to previous reviews, especially with regard to
older literature. Moreover, the authors particularly refer to a series of studies of thyroid function performed in a cohort of
patients at different stages of lithium treatment, who were followed up by their group from 1989 onwards.
Results: The main findings from this review included: a) lithium definitely affects thyroid function as repeatedly shown by studies
on cell cultures, experimental animals, volunteers, and patients; b) inhibition of thyroid hormone release is the critical
mechanism in the development of hypothyroidism, goitre, and, perhaps, changes in the texture of the gland which are detected
by ultrasonic scanning; c) compensatory mechanisms operate and prevent the development of hypothyroidism in the majority
of patients; d) when additional risk factors are present, either environmental (such as iodine deficiency) or intrinsic
(immunogenetic background), compensatory potential may be reduced and clinically relevant consequences may derive; e)
hypothyroidism may develop in particular during the first years of lithium treatment, in middle-aged women, and in the presence
of thyroid autoimmunity; f) thyroid autoimmunity is found in excess among patients suffering from affective disorders,
irrespective of lithium exposure; g) in patients who have been on lithium for several years, the outcome of hypothyroidism,
goitre, and thyroid autoimmunity do not much differ from those observed in the general population; h) hyperthyroidism and
thyroid cancer are observed rarely during lithium treatment.
Recommendations: Thyroid function tests (TSH, free thyroid hormones, specific antibodies, and ultrasonic scanning) should
be performed prior to starting lithium prophylaxis. A similar panel should be repeated at one year. Thereafter, annual
measurements of TSH may be sufficient to prevent overt hypothyroidism. In the presence of raised TSH or thyroid
autoimmunity, shorter intervals between assessments are advisable (4–6 months). Measurement of antibodies and ultrasonic
scanning may be repeated at 2-to-3-year intervals. The patient must be referred to the endocrinologist if TSH concentrations
are repeatedly abnormal, and/or goitre or nodules are detected. Thyroid function abnormalities should not constitute an
outright contraindication to lithium treatment, and lithium should not be stopped if a patient develops thyroid abnormalities.
Decisions should be made taking into account the evidence that lithium treatment is perhaps the only efficient means of reducing
the excessive mortality which is otherwise associated with affective disorders.
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Background
Abnormalities in thyroid function have concerned clini-
cians and patients since the introduction of lithium in the
treatment of manic-depression. Goitre was one of the first
described potential side effects of this treatment [1] and
prompted subsequent studies on the interactions between
lithium and thyroid function [2]. Moreover, it soon
became evident that lithium treatment is at times associ-
ated with clinical hypothyroidism [3]. Decades of clinical
use of lithium and availability of new diagnostic tools for
thyroid abnormalities have extended the interest to other
aspects, including autoimmunity, hyperthyroidism, and
morphological changes.
The advent of alternative treatments for recurrent affective
disorders warrants a review of the clinical relevance of
lithium-related side effects, including those regarding thy-
roid function. The amount of scientific papers dealing
with lithium and thyroid function totals several hundred;
therefore we shall refer to previous reviews, especially
with regard to older literature [4,5]. We will also refer to a
series of studies of thyroid function performed in a cohort
of 150 patients at different stages of lithium treatment,
who were followed up by our group from 1989 onwards
[6-9].
The following important points will also be addressed: a)
the emerging evidence that thyroid abnormalities, in par-
ticular autoimmunity, are found in excess among patients
suffering from affective disorders, irrespective of lithium
exposure [10,11]; b) the evidence that lithium treatment,
despite its potential toxicity and side effects, is perhaps the
only drug capable of reducing the excessive mortality
which is otherwise associated with affective disorders
[12,13].
Goitre and ultrasonic scan abnormalities
The goitrogenic effect of lithium was observed early after
its introduction in the treatment of manic-depression. In
1968, Schou and coworkers reported a prevalence of goi-
tre of 3.6% and calculated an annual incidence of 4%
among patients on continuous lithium compared with a
1% incidence in a geographically matched general popu-
lation [1]. Nowadays, despite such a long history, contro-
versy still persists regarding the relevance of lithium-
induced goitre. Large long-term prospective studies using
reliable methods of detection (i.e. ultrasonic scans) are
lacking, and a wide range of prevalence rates (0–60%) is
reported from existing cross-sectional studies (for review
see [4]). Differences in the methods of detection, together
with variation in the geographical origin of patients (espe-
cially related to iodine intake), are perhaps the main rea-
son for such discrepancies. The most reliable existing
study of goitre in manic-depressive patients, though cross-
sectional, is perhaps that by Perrild et al [14]. Ultrasoni-
cally determined thyroid size was larger than expected
(according to age and weight of subjects) among patients
treated with lithium for 1–5 years (44%) or more than 10
years (50%) than in patients who had never received lith-
ium (16%).
As the relevance of goitre among lithium-treated patients
is still debated, the attitude of clinicians varies: the main
question is whether or not TSH-suppressive treatment is
to be started in lithium patients as soon as goitre is
detected even in the absence of hypothyroidism [15,16].
Some authors even recommend prophylaxis with levothy-
roxine in all patients starting lithium if they come from
goitre-endemic areas [17]. Their suggestion was based on
an 87% prevalence found in lithium patients from a
region where the general prevalence ranged from 20% to
30%. On the other hand, Lazarus [15] does not argue in
favour of treatment, also based on the possible occurrence
of lithium-associated thyrotoxicosis (see the specific sec-
tion). There are other reasons for caution in the use of
TSH-suppressive levothyroxine. Besides the general limi-
tations of TSH-suppressive treatment including advanced
age, cardiovascular problems, and osteoporosis, one addi-
tional problem in lithium patients may regard their
acceptance of chronic polypharmacy. Unpublished data
from our cohort revealed that, after at least 10 years of
lithium treatment, up to two-thirds of patients were tak-
ing chronic psychotropic medication in addition to lith-
ium and 31% were taking chronic medication for other
medical conditions apart from levothyroxine (including
18% on antihypertensive medication).
Another relevant observation from our cohort is that the
rate of patients with a visible and/or palpable goitre
(which attained 51% when first examined [6]) decreased
at follow up [8,9], even in the absence of levothyroxine
treatment and despite continuous exposure to lithium.
This is similar to the results from the Whickham Survey of
the general population [18], and implies that the severity
of goitre and the presence of additional factors should be
taken into account in the decision of whether or not to
prescribe treatment with TSH-suppressive levothyroxine.
The latter, moreover, would not affect one of the mecha-
nisms underlying lithium-induced increase in thyroid vol-
ume, i.e. its direct effect on the growth of thyroid cells, as
shown in vitro [19].
With regard to ultrasonic scan abnormalities apart from
increased volume, in our cohort with at least six-year lith-
ium treatment, up to 97% of women and 69% of men
without evidence of thyroid circulating antibodies
showed abnormalities (reduced echogenicity, non-homo-
geneous echopattern, and/or presence of nodules) [8].
Ultrasonic scan abnormalities may indeed be associated
to the inhibition of thyroid hormone release, the mainClinical Practice and Epidemiology in Mental Health 2006, 2:23 http://www.cpementalhealth.com/content/2/1/23
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effect exerted by lithium on thyroid function [2]. A more
recent German ultrasound study reported different results,
as thyroid echogenicity was found to be similar between
20 patients who had been on lithium for at least 6 months
and 20 age- and gender-matched controls [20]. We have
addressed elsewhere the potential value of thyroid echog-
raphy in the identification of patients at risk of developing
autoimmune hypothyroidism during long-term lithium
therapy [21]. The relevance of thyroid nodules will be dis-
cussed in the section on tumours.
Hypothyroidism
Hypothyroidism, irrespective of association with goitre,
has been one of the main concerns regarding lithium
treatment since the early 1970s [3]. Several interactions
between lithium and thyroid function have been evi-
denced (for review see [4]). Lithium is concentrated by the
thyroid and inhibits thyroidal iodine uptake. It also inhib-
its iodotyrosine coupling, alters thyroglobulin structure,
and inhibits thyroid hormone secretion. The latter effect is
critical to the development of hypothyroidism and goitre.
Many studies have investigated prevalence rates of
hypothyroidism. As already mentioned with regard to goi-
tre, differences in criteria (for example overt versus sub-
clinical hypothyroidism) and study population (gender
ratio, geographical origin of patients, iodine intake, pro-
portion of subjects with autoimmunity, etc) may explain
the wide range of prevalence rates (0–23%) from existing
cross-sectional studies (for review see [4,5]). In a retro-
spective study of 718 lithium patients, Johnston and
Eagles [22] found a 10.4% prevalence of clinical hypothy-
roidism, calling for an upward revision of generally
quoted rates of '90s reviews (2–5%). They identified a
higher risk in women, especially those starting lithium in
middle age (hypothyroidism prevalence > 20%). They cal-
culated retrospectively annual incidence figures of 2.17%
in women and 0.68% in men, which are substantially
higher than the community incidences of hypothyroidism
reported by Vanderpump et al (0.41% and 0.06%) [18].
Kirov et al [23] have recently published a study of thyroid
disorders in 274 lithium patients, including 57 who had
been observed longitudinally for between 1 and 7 years.
The risk for hypothyroidism was especially increased in
women over the age of 50. Of the 33 women followed up
prospectively, 4 developed hypothyroidism, correspond-
ing to an incidence of 2.74%. The latter figure is a nearly
eight-fold increase over the mean incidence of 0.35%
among middle-aged women in the Whickham Survey
[18].
In our prospective evaluation [9], incidence of cases
requiring replacement treatment with levothyroxine
(2.1% in women and 0.3% in men) was very similar to the
incidence of hypothyroidism reported by the UK studies
[22,23]. In the absence of a control group, incidence may
be compared with published data from the general popu-
lation, but there may be wide variation due to differences
in geographical areas and in criteria for hypothyroidism.
Overt hypothyroidism is becoming rare as replacement
treatment is now prescribed in the presence of subclinical
hypothyroidism (raised TSH plus reduced thyroxine con-
centrations). Current epidemiological studies, including
the follow up of the Whickham Survey [18], usually focus
on intention-to-treat. On the other hand, lithium patients
often receive replacement treatment with levothyroxine in
the presence of repeated raised TSH concentration alone,
which may lead to an overestimation of incidence when
compared with community data. In our 10-year follow-up
study [9], we compared rates with the subset of data from
the Whickham Survey published by Tunbridge et al [24],
who included figures of raised TSH concentrations (above
6 µU/mL) alone. Thus, our conclusion that there is a sim-
ilarity between rates of hypothyroidism in lithium
patients and those in the general population [9], diverged
from the conclusions of the UK studies [22,23]. Perhaps,
the truth is somewhere between the two extremes. In any
case, whatever the proportion of cases of hypothyroidism
that can be attributed to lithium treatment, we confirmed
the relevance of other risk factors, such as gender and pres-
ence of thyroid autoimmunity. The hierarchy of risk
between our lithium-cohort and the community is simi-
lar, as the highest annual rates of hypothyroidism are
observed in antibody-positive subjects, followed by anti-
body-negative women, whereas risk is apparently null in
antibody-negative men from both settings.
Hyperthyroidism
Cases of hyperthyroidism have been associated with lith-
ium treatment since the 1970s [25], but less commonly
compared with hypothyroidism and goitre. Indeed, being
the main effect of lithium a reduction of thyroid hor-
mones, it has even been used in the treatment of thyrotox-
icosis [26]. There are conflicting opinions regarding the
relevance of hyperthyroidism during lithium treatment.
Sirota et al [27] reported nine cases although, based on the
relatively small number of case reports in the literature
and the diffusion of lithium treatment, they concluded
that "lithium therapy does not cause hyperthyroidism".
Conversely, Barclay et al [28] reported 14 cases and calcu-
lated retrospectively a higher than expected incidence of
hyperthyroidism. Of the 33 women followed up prospec-
tively by Kirov et al [23], one developed hyperthyroidism
over 146 patient-years. In our cohort, one case of hyper-
thyroidism was observed in a woman at the last follow-up
(to be published), when the observation period for
women totalled 680 patient-years, corresponding to an
annual rate of 0.1%. The latter rate does not diverge from
the incidence reported for the female general population
by the Whickham Survey [18].Clinical Practice and Epidemiology in Mental Health 2006, 2:23 http://www.cpementalhealth.com/content/2/1/23
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Antithyroid antibodies
Lithium affects many aspects of cellular and humoral
immunity  in vitro and  in vivo, but it is controversial
whether lithium per se can induce thyroid autoimmunity.
Prevalence of specific thyroid antibodies among lithium-
treated patients varies across studies. It is however impor-
tant to underline once again the effects of age and gender.
Women are known to express thyroid autoimmunity
more frequently than men. This tendency is more obvious
in the middle age range. Initial and final prevalence rates
from our lithium cohort (women, 21 to 27%; men, 4 to
10%) [9] were within the ranges observed in similar age
and gender subgroups from the Whickham Survey [18].
Several prospective studies, though reporting fluctuations
in antibody titres, failed to detect differences between pre-
and post-lithium prevalence rates of autoimmunity [29-
31]. However, an intriguing observation from our cohort
was the development of thyroid antibodies in young sub-
jects of both sexes within a few years of lithium exposure
[7]. Nevertheless, annual incidence rates in our patients
after several years of lithium treatment (1.3–1.5%) did
not much differ from the ranges reported for the general
population, with maximum values of approximately 2%
in women aged over 45 [18,24].
It is noteworthy, as mentioned above, that thyroid
autoimmunity has been found associated with affective
disorders, irrespective of treatment [11,32]. Kupka et al
[11] found thyroperoxidase antibodies in 64 of 226
(28%) bipolar outpatients. In the latter, autoimmunity
was associated with thyroid failure, but not with age, gen-
der, mood state, rapid cycling, or lithium exposure.
Indeed, 12 of 35 (34.3%) who had never received lithium
had thyroperoxidase antibodies.
Tumours
Lithium treatment has not been associated with thyroid
tumours, apart from nodular goitre. In our cohort with at
least 6 years of lithium treatment, ultrasound revealed
nodules in 47% of women and 24% of men [8]. Similar
prevalence rates have been found in the Sardinian general
population (to be published). Multinodular goitre is par-
ticularly prevalent in iodine-deficiency areas, whereas
female gender and advancing age represent additional risk
factors. The major concern regards the potential malig-
nant nature of nodules, which requires further diagnostic
procedures, such as fine needle aspiration with cytology.
The latter revealed malignancy (papillary carcinoma) in a
woman from our cohort at the last follow-up (to be pub-
lished). No other cases were evidenced and the annual
incidence rate in women (over 680 patient-years) was
0.1%.
Conclusion
The clinical relevance of thyroid dysfunction during long-
term lithium is an important issue, considering that lith-
ium still represents the gold standard among prophylactic
treatments of manic-depression several decades after its
introduction. Lithium definitely affects thyroid function
as repeatedly shown by studies on cell cultures, experi-
mental animals, volunteers, and patients. Inhibition of
thyroid hormone release is the critical mechanism in the
development of hypothyroidism, goitre, and, perhaps,
changes in the texture of the gland which are detected by
ultrasonic scanning. Compensatory mechanisms operate
and prevent the development of hypothyroidism in the
majority of patients. When additional risk factors are
present, either environmental (such as iodine deficiency,
dietary goitrogens, cigarette smoking) or intrinsic (immu-
nogenetic background), compensatory potential may be
reduced and clinically relevant consequences may derive.
Hypothyroidism may occur in particular in middle aged-
women and/or in the presence of thyroid autoimmunity.
Hyperthyroidism and thyroid cancer are less common.
On clinical grounds, the following procedures are recom-
mended in lithium patients. Assessment of thyroid func-
tion prior to starting lithium prophylaxis should include
measurement of serum concentrations of TSH, FT3, FT4,
AbTPO, and ultrasonic scanning. A similar panel should
be repeated at one year. Thereafter, annual measurements
of TSH may be sufficient to prevent overt hypothyroidism.
In the presence of subclinical hypothyroidism (raised
TSH), shorter intervals between assessments are advisable
(4–6 months). Measurement of AbTPO and ultrasonic
scanning may be repeated at 2-to-3-year intervals. The
patient must be referred to the endocrinologist if TSH con-
centrations are repeatedly abnormal, and/or goitre or
nodules are detected.
Finally, in our opinion, in view of the availability of ade-
quate therapeutic means, the presence of thyroid function
abnormalities should not constitute an outright contrain-
dication to lithium treatment, contrary to arguments
often put forward and practiced to date. Similarly, lithium
should not be stopped if a patient develops thyroid abnor-
malities. Any decision should be made taking into
account the evidence that lithium treatment, despite its
potential toxicity and side effects, is perhaps the only effi-
cient means of reducing the excessive mortality which is
otherwise associated with affective disorders.
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